Jacques Van Snick
25Patents
8h-index
27Co-inventors
75Inventor score
Filing activity: Sep 19, 1988 → Sep 23, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5246701A | Method for inhibiting production of IgE by using IL-9 inhibitors | Emerging Cross-Sectional Technologies | 22 | Expired |
| US5116951A | Substantially pure interleukin-9 receptor and uses thereof | Human Necessities | 19 | Expired |
| US5157112A | Antibodies immunoreactive with the T-cell growth factor, P40 | Emerging Cross-Sectional Technologies | 18 | Expired |
| US5208218A | T cell growth factor glycoproteins | Emerging Cross-Sectional Technologies | 17 | Expired |
| US7371383B2 | Recombinant anti-interleukin-9 antibodies | Chemistry; Metallurgy | 16 | Expired |
| US5180678A | Uses of substantially pure interleukin-9 receptor | Human Necessities | 14 | Expired |
| US5132109A | Method for inhibiting production of IGE and method for enhancing production of IGG using interleukin 9 and inhibitors thereof | Human Necessities | 14 | Expired |
| US5164317A | Method for enhanced growth and proliferation of mast cells | Chemistry; Metallurgy | 12 | Expired |
| US6716809B1 | Mage-A3 peptides presented by HLA class molecules | Chemistry; Metallurgy | 6 | Expired |
| US6645486B1 | Method of treatment with IL-9 conjugate | Human Necessities | 3 | Expired |
| US9518112B2 | TGF-β1 specific antibodies and methods and uses thereof | Physics | 1 | Active |
| US7157091B1 | MAGE-A1 peptides presented by HLA class II molecules | Emerging Cross-Sectional Technologies | 1 | Expired |
| US10947303B2 | TGF-ß1 specific antibodies and methods and uses thereof | Physics | 1 | Active |
| US10723793B2 | TGF-β3 specific antibodies and methods and uses thereof | Physics | 1 | Active |
| US6328955A | Method for regulating IL-10 with IL-9, and applications thereof | Emerging Cross-Sectional Technologies | 0 | Expired |
| US12221477B2 | TGF-β3 specific antibodies and methods and uses thereof | Physics | 0 | Active |
| US5789237A | Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor | Human Necessities | 0 | Expired |
| US11485780B2 | TGF-β3 specific antibodies and methods and uses thereof | Physics | 0 | Active |
| US5962269A | Methods for producing antibodies which specifically bind to interleukin-9 receptor | Human Necessities | 0 | Expired |
| US5750377A | Process for preparing mammalian T cell growth factor P40 | Human Necessities | 0 | Expired |
| US10035851B2 | TGF-β1 specific antibodies and methods and uses thereof | Physics | 0 | Active |
| US5587302A | T cell growth factor | Human Necessities | 0 | Expired |
| US7094396B2 | Method for making cytokine specific antibodies and uses thereof | Human Necessities | 0 | Expired |
| US11957751B2 | TGF-β1 specific antibodies and methods and uses thereof | Physics | 0 | Active |
| US6558660B2 | Method for regulating IL-10 with IL-9, and applications thereof | Emerging Cross-Sectional Technologies | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.